Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics – Session #1

Join us for a Live-Virtual Patient Exam Room and an opportunity to earn an Uber Eats credit!


Tuesday, June 7, 2022

6:30 PM – 7:30 PM EDT



Provided by Integrity Continuing Education, Inc.


This program is supported by an educational grant from AstraZeneca Pharmaceuticals.


This interactive activity will provide relevant clinicians with a greater understanding of the unmet needs in severe asthma, the alarmin pathway, and novel biologic therapies and their potential positioning within the therapeutic landscape. This may lead to improved treatment practices and better outcomes for the broader severe asthma population.

After a brief lecture, learners will enter the virtual exam room where they’ll have an opportunity to work with colleagues in solving two clinical cases.

We invite and encourage attendees to turn on their cameras and microphones in order to best engage with one another.



Michael S. Blaiss, MD, FACAAI
Clinical Professor
Medical College of Georgia at Augusta University
Augusta, Georgia


Michael E. Wechsler, MD, MMSc
Director, The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health                                                                                                                                                                                                          Denver, Colorado


This activity is intended for US-based asthma specialists, including allergists, immunologists, and pulmonologists, as well as specialty nurse practitioners and physician assistants.


Upon completion of this educational activity, participants should be able to:

  • Describe the unmet needs with current severe asthma therapies and the contributions of the airway epithelium and hyperresponsiveness in the disease
  • Explain the involvement of alarmins in severe asthma and the rationale for targeting upstream cytokines in controlling the disease
  • Apply newly approved treatments that address the alarmin pathway in severe asthma in appropriate patient types


There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Participate in the live program
  • Complete the posttest and the evaluation form at the end of the program

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Michael S. Blaiss, MD, FACAAI
Consulting Fees: ALK-Abello Inc., GlaxoSmithKline, Merck, Perrigo, Pfizer, Regeneron, Sanofi, TerSera​
Speakers’ Bureaus: ALK-Abello Inc., Merck, Regeneron, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: AstraZeneca, Cohero, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Restorbio, Sanofi, Sentien, Teva
Contracted Research: AstraZeneca, Sanofi

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)

Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


On the day of the program, you may access the event by going to the following link:

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME CreditTM. To do so, you must participate in the live-virtual activity and complete the posttest and evaluation following the event. A statement of credit will be issued within four weeks of submission of a completed activity evaluation form.

To qualify for a $20 Uber Eats credit, you must complete the following steps:

  1. Preregister for one live-virtual severe asthma session
  2. Complete the program pretest
  3. Attend the live-virtual severe asthma session
  4. Complete the posttest/evaluation at the end of the program

The pretest and posttest/evaluation forms will be provided to you electronically before, during, and/or after the program. The first 15 registrants to complete all of the above steps will receive a $20 Uber Eats credit via email within 2 weeks of completion.